Researchers published an engineered UGA‑suppressor tRNA designed to broaden AAV‑based therapeutic reach by enabling in vivo suppression of UGA stop codons, potentially allowing disease‑agnostic payload delivery. The Nature Biotechnology paper details design, in vivo testing and how suppressor tRNAs could expand the set of genetic lesions that are addressable via AAV while preserving translational fidelity. The tool aims to enable flexible protein expression from single AAV vectors for conditions where premature stop codons or truncations limit therapy. The authors emphasize delivery compatibility and safety profiling in preclinical systems as next steps. Why it matters: the work provides a modular genetic tool to widen AAV payload options, with immediate relevance to gene‑therapy developers seeking compact, versatile approaches for monogenic and multi‑domain proteins.